OneMedNet Corporation regains Nasdaq compliance after filing financial reports and announces new strategic initiatives for growth.
Quiver AI Summary
OneMedNet Corporation announced it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Form 10-Q reports for the first three quarters of 2024. CEO Aaron Green expressed satisfaction in being current with financial reporting, allowing the company to focus on growth. In the second half of 2024, OneMedNet appointed new leadership, including an interim CFO and key marketing and business development roles, and signed an agreement with Bayer’s AI Innovation Platform. The company also raised approximately $6.4 million in private placements, enhanced its data management services using Generative AI, and refreshed its Board of Directors. OneMedNet aims to leverage its innovative platform to capture significant market share in the Real World Data sector.
Potential Positives
- OneMedNet Corporation regained compliance with Nasdaq Listing Rule 5250(c)(1), indicating the company is current on its financial reporting responsibilities.
- The appointment of key management positions, including a new Chief Financial Officer and Director of Business Development, suggests a focus on enhancing financial reporting and expanding commercial presence.
- The company successfully raised approximately $6.4 million in private placements, improving its liquidity and financial positioning.
- OneMedNet is enhancing its technological capabilities by leveraging Generative AI and launching its 2.0 generation indexer, which could improve data search and indexing accuracy, positioning the company advantageously in the Real World Data market.
Potential Negatives
- The company's prior non-compliance with Nasdaq Listing Rule 5250(c)(1) raises concerns about its financial reporting practices and governance.
- The announcement of an interim CFO suggests potential instability or lack of confidence in the finance leadership.
- The mention of risks associated with investing in Bitcoin highlights potential volatility and uncertainty in the company’s treasury management strategy.
FAQ
What is OneMedNet Corporation's recent achievement with Nasdaq?
OneMedNet has regained compliance with Nasdaq Listing Rule 5250(c)(1) by filing its periodic reports for Q1, Q2, and Q3 of 2024.
Who is the new Chief Financial Officer at OneMedNet?
Bob Golden has been appointed as the interim Chief Financial Officer to oversee improvements in financial reporting processes.
What is OneMedNet's iRWD™ platform?
OneMedNet's iRWD™ platform manages diverse clinical data types, providing secure access to immense Real World Data for research opportunities.
How has OneMedNet improved its operations recently?
The company hired new executives, enhanced data services with Generative AI, and raised approximately $6.4M in private placements to improve liquidity.
What industries does OneMedNet serve with its data solutions?
OneMedNet provides services across various domains, including oncology, cardiology, rare diseases, and women's health, to advance patient outcomes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ONMD Hedge Fund Activity
We have seen 11 institutional investors add shares of $ONMD stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DISCOVERY CAPITAL MANAGEMENT, LLC / CT added 2,301,791 shares (+inf%) to their portfolio in Q3 2024
- CKW FINANCIAL GROUP removed 476,709 shares (-82.5%) from their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC removed 83,188 shares (-44.9%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC added 49,899 shares (+inf%) to their portfolio in Q3 2024
- HRT FINANCIAL LP removed 42,620 shares (-100.0%) from their portfolio in Q3 2024
- UBS GROUP AG added 37,766 shares (+inf%) to their portfolio in Q3 2024
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 35,827 shares (-51.8%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MINNEAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) based on the filing of its periodic reports on Form 10-Q for the fiscal quarters ended March 31, June 30 and September 30, 2024. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming compliance with the Rule.
Aaron Green, Chief Executive Officer, stated, “We are pleased to have filed our financial results for the first three quarters of 2024. Together with the recently completed reaudit of our 2023 financial statements, we are now current on our periodic financial reporting and can focus on growing our business going forward.”
During the second half of 2024, we developed and started to execute on our strategic plan by:
-
Appointing Bob Golden as Chief Financial Officer, on a interim basis to oversee enhancements in the Company’s financial reporting processes.
-
Hiring a Director of Business Development, Margaret Nash, and Vice President of Marketing, Michael Wong, to continue to build our commercial presence with Life Science organizations, additionally recently signing an agreement with Bayer’s AI Innovation Platform (AIIP) announced in early December.
-
Enhancing our Data De-Identification and curation service leveraging Generative AI and deploying OneMedNet’s 2.0 generation indexer OMNi, to improve the speed and accuracy of data searching and indexing.
-
Refreshing the composition of the Company’s Board of Directors with three new directors who have relevant industry, financial and public company expertise.
-
Improving liquidity by raising approximately $6.4M in private placements with Off the Chain Capital and an affiliate of Discovery Capital Management.
-
Enhancing treasury management with a Bitcoin on the balance sheet strategy.
OneMedNet is now in a position to take advantage of the growing Real World Data market with a meaningful market share.
About OneMedNet Corporation
OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, ECGs, EEGs, prescriptions, physician notes, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.
OneMedNet’s platform is designed to address diverse clinical requirements across various domains, such as rare diseases, central nervous system disorders, oncology, cardiology and women’s health. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timeline for the Company to regain compliance with the listing rules of The Nasdaq Stock Market LLC relating to maintaining a minimum bid price of $1.00 per share and a minimum value of listed securities; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email:
[email protected]
SOURCE: ONEMEDNET CORPORATION